Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Melanoma is a highly heterogeneous neoplasm, composed of subpopulations of tumor cells with distinct molecular and biological phenotypes and genotypes. In this study, to determine the genetic heterogeneity between primary and metastatic melanoma in Korean melanoma patients, we evaluated several well-known genetic alterations of melanoma. In addition, to elucidate the clinical relevance of each genetic alteration and heterogeneity between primary and metastatic lesions, clinical features and patient outcome were collected. Materials and Methods In addition to clinical data, BRAF, NRAS, GNAQ/11mutation and KIT amplification data was acquired from an archived primary Korean melanoma cohort (KMC) of 188 patients. Among these patients, 43 patients were included for investigation of tumor heterogeneity between primary melanoma and its corresponding metastatic lesions. Results Overall incidence of genetic aberrations of the primary melanomas in KMC was 17.6% of BRAF V600, 12.6% of NRASmutation, and 28.6% of KIT amplification. GNAQ/11mutation was seen in 66.6% of the uveal melanoma patients. Patients with BRAF mutation were associated with advanced stage and correlated to poor prognosis (p < 0.01). Among 43 patients, 55.8% showed heterogeneity between primary and metastatic lesion. The frequency of BRAF mutation and KIT amplification significantly increased in the metastatic lesions compared to primary melanomas. GNAQ/11mutation showed 100% homogeneity in uveal melanoma patients. Conclusion Our data demonstrated heterogeneity between primary melanomas and corresponding metastatic lesions for BRAF, NRAS mutation and KIT amplification. However, GNAQ/11 mutation was genetically homogeneous between primary and metastatic melanoma lesions in uveal melanoma.
Abstract
Purpose Melanoma is a highly heterogeneous neoplasm, composed of subpopulations of tumor cells with distinct molecular and biological phenotypes and genotypes. In this study, to determine the genetic heterogeneity between primary and metastatic melanoma in Korean melanoma patients, we evaluated several well-known genetic alterations of melanoma. In addition, to elucidate the clinical relevance of each genetic alteration and heterogeneity between primary and metastatic lesions, clinical features and patient outcome were collected. Materials and Methods In addition to clinical data, BRAF, NRAS, GNAQ/11mutation and KIT amplification data was acquired from an archived primary Korean melanoma cohort (KMC) of 188 patients. Among these patients, 43 patients were included for investigation of tumor heterogeneity between primary melanoma and its corresponding metastatic lesions. Results Overall incidence of genetic aberrations of the primary melanomas in KMC was 17.6% of BRAF V600, 12.6% of NRASmutation, and 28.6% of KIT amplification. GNAQ/11mutation was seen in 66.6% of the uveal melanoma patients. Patients with BRAF mutation were associated with advanced stage and correlated to poor prognosis (p < 0.01). Among 43 patients, 55.8% showed heterogeneity between primary and metastatic lesion. The frequency of BRAF mutation and KIT amplification significantly increased in the metastatic lesions compared to primary melanomas. GNAQ/11mutation showed 100% homogeneity in uveal melanoma patients. Conclusion Our data demonstrated heterogeneity between primary melanomas and corresponding metastatic lesions for BRAF, NRAS mutation and KIT amplification. However, GNAQ/11 mutation was genetically homogeneous between primary and metastatic melanoma lesions in uveal melanoma.
참고문헌 (29)
- Alexandrov LB, "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
- Fecher LA, "Toward a molecular classification of melanoma", J Clin Oncol, 25, pp.1606~1620 (2007)
- Miller AJ, "Melanoma", N Engl J Med, 355, pp.51~65 (2006)
- Cancer Genome Atlas Network, "Genomic classification of cutaneous melanoma", Cell, 161, pp.1681~1696 (2015)
- Kong Y, "Large-scale analysis of KIT aberrations in Chinese patients with melanoma", Clin Cancer Res, 17, pp.1684~1691 (2011)
- Roesch A, "A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth", Cell, 141, pp.583~594 (2010)
- Yancovitz M, "Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma", PLoS One, 7, pp.e29336~ (2012)
- Yun J, "KIT amplification and gene mutations in acral", mucosal melanoma in Korea, 2011, pp.119, 330~335
- Van Raamsdonk CD, "Mutations in GNA11 in uveal melanoma", N Engl J Med, 363, pp.2191~2199 (2010)
- Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
- Flaherty KT, "Mutation-driven drug development in melanoma", Curr Opin Oncol, 22, pp.178~183 (2010)
- Hiley C, "Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine", Genome Biol, 15, pp.453~ (2014)
- Woodman SE, "New strategies in melanoma: molecular testing in advanced disease", Clin Cancer Res, 18, pp.1195~1200 (2012)
- Greaves WO, "Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma", J Mol Diagn, 15, pp.220~226 (2013)
- 오창모, "Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea", Cancer Research and Treatment, 50(3), pp.729~737 (2018), 대한암학회
- Thompson JF, "Cutaneous melanoma", Lancet, 365, pp.687~701 (2005)
- Balch CM, "Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system", J Clin Oncol, 19, pp.3622~3634 (2001)
- Long GV, "Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma", J Clin Oncol, 29, pp.1239~1246 (2011)
- Fecher LA, "The MAPK pathway in melanoma", Curr Opin Oncol, 20, pp.183~189 (2008)
- Edlundh-Rose E, "NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing", Melanoma Res, 16, pp.471~478 (2006)
- Ugurel S, "B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis", PLoS One, 2, pp.e236~ (2007)
- Bauer J, "BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site", Pigment Cell Melanoma Res, 24, pp.345~351 (2011)
- Ellerhorst JA, "Clinical correlates of NRAS and BRAF mutations in primary human melanoma", Clin Cancer Res, 17, pp.229~235 (2011)
- Almendro V, "Cellular heterogeneity and molecular evolution in cancer", Annu Rev Pathol, 8, pp.277~302 (2013)
- Thomas NE, "Tandem BRAF mutations in primary invasive melanomas", J Invest Dermatol, 122, pp.1245~1250 (2004)
- Patton EE, "BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma", Curr Biol, 15, pp.249~254 (2005)
- Colombino M, "BRAF", NRAS mutation frequencies among primary tumors and metastases in patients with melanoma, 2012, pp.30, 2522~2529
- Greene VR, "Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma", J Invest Dermatol, 129, pp.1483~1488 (2009)
- Lin J, "Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression", Br J Cancer, 104, pp.464~468 (2011)